Search
Bicalutamide
go.drugbank.com/drugs/DB01128ApprovedInvestigationalBicalutamide binds to the androgen receptor. … Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.
Categories: Antiandrogens, non-steroidalProducts: Nu-bicalutamideOxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitIn 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009). … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth
Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalUnlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. … FDA approved on July 1, 2011.
Products: Nb-rivaroxabanDiphenylpyraline
go.drugbank.com/drugs/DB01146ApprovedAntihistamines prevent, but do not reverse, responses mediated by histamine alone. … Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells.
Mixtures: Emercreme No4 Ont EfaSynonyms: 4-(benzhydryloxy)-N-methylpiperidineSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]
Levallorphan
go.drugbank.com/drugs/DB00504ApprovedIt should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants … An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … [L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States
Theophylline
go.drugbank.com/drugs/DB00277ApprovedInvestigationalA methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine recep...
Mixtures: NEO ASMA, NEO NAPACINProducts: NEO NAPACIN, TEOFILINA RETARD MK 300 MGRisperidone
go.drugbank.com/drugs/DB00734ApprovedInvestigational[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways … [L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Nu-risperidone, Nb-risperidoneBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.